Funded Health Care Startups in Houston
Among the 25 Houston-area health care companies shown (sorted by round date descending), the largest disclosed amount is Evaheart’s $90M Series A on 2023-0…
Among the 25 Houston-area health care companies shown (sorted by round date descending), the largest disclosed amount is Evaheart’s $90M Series A on 2023-03-09, which dwarfs the next-largest disclosed rounds (Procyrion’s $48M on 2024-02-05, then March Biosciences at $28M on 2024-10-23; most other disclosed entries cluster below $20M). Several funding events concentrate in a 2024 window: 12 of the 25 rows are dated in 2024 (from 2024-06-03 through 2024-11-08), with multiple mid-size rounds such as March Biosciences ($28M, 2024-10-23), Starling Medical ($7M, 2024-09-18), and 7 Hills Pharma ($5M, 2024-06-03). Stage and disclosure are mixed: 6 rows list “Series Unknown” and 3 list “undisclosed,” while the only explicitly “Seed” entries include RadioClash ($810K, 2024-11-08) and AIM7 ($1M, 2022-11-22). The temporal range spans 2020-07-15 (Preventice Solutions) through 2025-10-30 (Lightning Step Technologies), with the most recent disclosed round being Koda Health’s $12M on 2025-09-15; the oldest disclosed amount shown is Preventice Solutions’ $137M (2020-07-15).
Most recent rounds
25 shownRelated listings
Frequently asked
What stands out in round size distribution for Houston health care here, and is there a clear top outlier?
Yes: Evaheart’s $90M on 2023-03-09 is the only disclosed round above $50M, and it sits well above the next-largest disclosed rounds at $48M (Procyrion, 2024-02-05) and $28M (March Biosciences, 2024-10-23). The rest of the disclosed amounts shown are generally below $20M, including $19M (Motif Neurotech, 2024-01-24) and $16M (Vivante Health, 2022-03-08).
Do the recent rounds cluster in time, especially in 2024?
The page shows a dense 2024 cluster: 12 of the 25 rows are dated in 2024, spanning 2024-02-05 (Procyrion) through 2024-11-08 (RadioClash). Within that window, disclosed mid-to-upper rounds include $28M (March Biosciences, 2024-10-23), $19M (Motif Neurotech, 2024-01-24), and $12M (Koda Health is 2025-09-15, but the 2024 analogs include Starling Medical’s $7M on 2024-09-18 and Prana Thoracic’s $2M on 2024-06-18).
How much of this list is uncertain on stage or amount (Series Unknown vs undisclosed), and does that affect the “largest round” read?
Stage is frequently not specified: 6 rows are labeled “Series Unknown,” and 3 rows are “undisclosed” for amount (including Lightning Step Technologies on 2025-10-30 and Spark Biomedical on 2025-08-19). Because the largest disclosed amount comes from Evaheart’s $90M (2023-03-09), the biggest-round conclusion among disclosed figures does not depend on those undisclosed entries.
What stage mix dominates compared with later-stage rounds (e.g., Series A/B/E) in the disclosed set?
Series A appears repeatedly with disclosed amounts such as Evaheart $90M (2023-03-09), March Biosciences $28M (2024-10-23), and Motif Neurotech $19M (2024-01-24), indicating a strong Series A skew versus single-appearance later stages like Series E (Procyrion $48M on 2024-02-05) and Series B (Decisio Health $19M on 2022-03-28). Seeds are present but smaller in disclosed size, such as RadioClash $810K (2024-11-08) and AIM7 $1M (2022-11-22).
Are there notable extremes on the low end of disclosed funding as well as the high end?
The smallest disclosed amount shown is Abeona’s $50K Pre-Seed on 2024-02-04, which is far below other small disclosed rounds like Paradocs Health at $170K (2024-08-01) and Galen Data at $350K (2023-11-14). On the high end, Evaheart’s $90M (2023-03-09) creates a wide disclosed range from $50K to $90M within this Houston health care set.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.